Early investigational agents for the treatment of rosacea: drugs in phase I and II clinical development [0.03%]
玫瑰痤疮治疗的早期研究药物：I期和II期临床在研药物
Shannon K Moran,Summer C Wong,Sarah L Taylor et al.
Shannon K Moran et al.
Introduction: Rosacea is a multifactorial chronic dermatologic condition with a psychosocial burden for patients. There are topical, systemic, laser, and light treatments FDA-approved, but many patients remain under- or n...
Investigational gene expression inhibitors for the treatment of idiopathic pulmonary fibrosis [0.03%]
特发性肺纤维化治疗的试验性基因表达抑制剂
Paolo Spagnolo,Roberto Tonelli,Marco Mura et al.
Paolo Spagnolo et al.
Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial lung disease of unknown cause that occurs primarily in older adults and is associated with poor quality of life and substa...
Metabolic dysfunction and insulin sensitizers in acute and chronic disease [0.03%]
代谢异常和胰岛素增敏剂在急性和慢性疾病中的作用
Jerry R Colca,Kyle S McCommis
Jerry R Colca
Introduction: The concept of insulin resistance has been a major topic for more than 5 decades. While there are several treatments that may impact insulin resistance, this pathology is uniquely addressed by mitochondriall...
Kosuke Murakami,Shiki Takamura,Kazuhiro Kakimi et al.
Kosuke Murakami et al.
Introduction: Recent clinical trials show the efficacy of immune checkpoint inhibitors (ICIs) or a combination of ICI and poly (ADP-ribose) polymerase (PARP) inhibitors for advanced or recurrent endometrial cancer. Howeve...
The role of 5-HT modulation in opioid withdrawal and neonatal opioid withdrawal syndrome: mechanisms and potential serotonergic targets [0.03%]
5-羟色胺能调控在阿片类药物脱毒及新生儿戒断综合征中的作用：机制和潜在的血清素能治疗靶点
Kevin Lam,Gary Peltz,Walter K Kraft
Kevin Lam
Introduction: Opioid use disorder and neonatal opioid withdrawal syndrome are persisting consequences of the opioid epidemic in the United States. Current pharmacologic approaches primarily utilize opioid replacement ther...
First-in-human study on tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of XKH001, a recombinant humanized monoclonal antibody against IL-25 in healthy Chinese volunteers [0.03%]
XKH001在健康受试者中的耐受性、药代动力学及药效学Ⅰ期临床研究
Hong Zhang,Wenbo Zheng,Ran Peng et al.
Hong Zhang et al.
Background: XKH001 is a recombinant humanized IgG1 monoclonal antibody against IL-25 for the treatment of type 2 inflammatory diseases. This study aimed to evaluate the tolerability, pharmacokinetics, and pharmacodynamics...
Tolerability, safety, and pharmacokinetics of GR1603 injection in healthy subjects: a randomized, double-blind, placebo-controlled single-dose escalation clinical trial [0.03%]
GR1603注射液在健康受试者中的耐受性、安全性及药代动力学：随机、双盲、安慰剂对照的单次递增剂量临床试验
Xin Huang,Xiang Hong,Shuang Yang et al.
Xin Huang et al.
Background: GR1603 is a monoclonal antibody targeting the type I interferon receptor. The aim of this study was to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of GR1603 in heal...
Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction [0.03%]
Survodutide在MASH中的作用：连接肝代谢功能障碍与全身代谢功能障碍之间的关系
Eda Kaya,Yusuf Yilmaz,Naim Alkhouri
Eda Kaya
Introduction: Glucagon-like peptide-1 receptor (GLP-1 R) agonists have demonstrated remarkable effectiveness in the treatment of obesity and type 2 diabetes. Although these agents provide beneficial effects for metabolic ...
Drugs stimulating insulin secretion in early clinical development for the treatment of type 1 diabetes: what's new? [0.03%]
一类新型促胰岛素分泌药物在1型糖尿病治疗中的早期临床开发进展展望
Xinyuan Ning,Kashif M Munir,Stephen N Davis
Xinyuan Ning
Introduction: Type 1 diabetes is a chronic autoimmune condition characterized by the selective destruction of insulin-producing beta cells in the pancreas. The etiology of T1D is multifactorial, with a combination of gene...
Relaxin agonists under preclinical and early clinical investigation for the treatment of heart failure [0.03%]
在研的用于治疗心力衰竭的松弛素激动剂类药物
Ashwin Ajay,Priyanga Biju,Hanan Ajay et al.
Ashwin Ajay et al.
Introduction: Acute failure is a critical condition, encompassed by the sudden or progressive onset of symptoms or signs of congestion. The treatment strategies available are mainly supportive and do not improve mortality...